DiscoverFollow the GradientFrom science risk to market fit - Cradle’s Stef van Grieken on building a biotech venture in Europe
From science risk to market fit - Cradle’s Stef van Grieken on building a biotech venture in Europe

From science risk to market fit - Cradle’s Stef van Grieken on building a biotech venture in Europe

Update: 2025-07-10
Share

Description

Most founders wait until Series A to clean up their cap table. Stef did the opposite - and spent $70K upfront just to get the foundations right.

As co-founder of Cradle, he built a biotech company for global scale from day one: navigating European legal complexity, validating science in skeptical labs, and paying early customers out of pocket to prove it worked.

In this episode, we get into:

  • ​Why Cradle paid its first two customers—and how that unlocked top-tier pharma clients
  • ​How to structure your company early to avoid massive headaches later
  • ​Why European startup culture struggles with ambition—and what needs to change
  • ​How to hire ML talent in Europe when OpenAI is knocking on the same doors


🟢 And before you go, subscribe to our free newsletter at ⁠⁠⁠⁠⁠⁠⁠followthegradient.io⁠⁠⁠⁠⁠⁠⁠. Twice a week, we break down startup and tech news, share exclusive insights from our podcast guests, highlight top job openings from European startups, and provide food for thought you won’t find anywhere else. 🟡

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

From science risk to market fit - Cradle’s Stef van Grieken on building a biotech venture in Europe

From science risk to market fit - Cradle’s Stef van Grieken on building a biotech venture in Europe

Follow the Gradient